Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: A propensity score matched analysis

Journal of Clinical Oncology

Volumn 35, Issue 5, 2017, Pages 515-522

  Mokdad, Ali A ^a   Minter, Rebecca M ^a   Zhu, Hong ^a   Augustine, Mathew M ^a   Porembka, Matthew R ^a   Wang, Sam C ^a   Yopp, Adam C ^a   Mansour, John C ^a   Choti, Michael A ^a   Polanco, Patricio M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CONFERENCE PAPER; EARLY CANCER; FEMALE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPENSITY SCORE; SURGICAL MARGIN; SURGICAL MORTALITY; UPFRONT RESECTION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CHEMORADIOTHERAPY; DRUG EFFECTS; KAPLAN MEIER METHOD; NEOADJUVANT THERAPY; PANCREAS; PANCREAS TUMOR; PANCREATECTOMY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; STATISTICS AND NUMERICAL DATA; SURGERY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 85012863530     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.5081     Document Type: Conference Paper

References (33)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. National Cancer Institute: SEER stat fact sheets: Pancreas cancer. http://seer.cancer.gov/ statfacts/html/pancreas.html
3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267, 2010
4. Li D, O'Reilly EM: Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 42:134-143, 2015
5. National Comprehensive Cancer Network: Pancreactic adenocarcinoma (version 2.2015). http:// www.nccn.org/professionals/physician-gls/f-guidelines. asp#pancreatic
6. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004
7. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007
8. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304: 1073-1081, 2010
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776-782; discussion 782-784, 1999
10. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008
11. Tzeng CW, Tran Cao HS, Lee JE, et al: Treatment sequencing for resectable pancreatic cancer: Influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 18:16-24; discussion 24-25, 2014
12. Aloia TA, Lee JE, Vauthey JN, et al: Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 204:347-355, 2007
13. Mayo SC, Gilson MM, Herman JM, et al: Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 214:33-45, 2012
14. Winner M, Goff SL, Chabot JA: Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Semin Oncol 42:86-97, 2015
15. American College of Surgeons: National cancer database. https://www.facs.org/quality-programs/ cancer/ncdb
16. Mattei A: Estimating and using propensity score in presence of missing background data: An application to assess the impact of childbearing on wellbeing. Stat Methods Appl 18:257-273, 2008
17. Austin PC: The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242-1258, 2014
18. Sekhon J: Multivariate and propensity score matching software with automated balance optimization: The Matching package for R. J Stat Softw 42: 1-52, 2011
19. R Core Team: R: A language and environment for statistical computing. https://www.R-project.org/
20. Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083-3107, 2009
21. Tsai S, Evans DB: Therapeutic advances in localized pancreatic cancer. JAMA Surg 10.1001/jamasurg.2016. 1113 [epub ahead of print on June 8, 2016]
22. Golcher H, Brunner TB, Witzigmann H, et al: Neoadjuvant chemoradiation therapy with gemcitabine/ cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: Results of the first prospective randomized phase II trial. Strahlenther Onkol 191:7-16, 2015
23. Wagner M, Redaelli C, Lietz M, et al: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586-594, 2004
24. Glant JA, Waters JA, House MG, et al: Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery 150: 607-616, 2011
25. Kneuertz PJ, Cunningham SC, Cameron JL, et al: Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: Trends and lessons learned from a large, single institution experience. J Gastrointest Surg 15: 1917-1927, 2011
26. Christians KK, Heimler JW, George B, et al: Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery 159: 893-900, 2016
27. Papalezova KT, Tyler DS, Blazer DG, III, et al: Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol 106:111-118, 2012
28. Ferrone CR, Brennan MF, Gonen M, et al: Pancreatic adenocarcinoma: The actual 5-year survivors. J Gastrointest Surg 12:701-706, 2008
29. Cheng T-Y, Sheth K, White RR, et al: Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 13:66-74, 2006
30. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
31. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013
32. Neoptolemos JP, Palmer D, Ghaneh P, et al: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr LBA4006)
33. National Institutes of Health: ClinicalTrials.gov. https://clinicaltrials.gov/